RAND Corporation Provides Objective Research Services and Public Policy Analysis

  • A novel coronavirus illustration

    Content

    COVID-19 Pandemic: Insights from RAND

    RAND research and expertise can inform immediate policy responses to address the disastrous effects of COVID-19—and help aid in recovery long after the disease stops spreading.

  • Truth Decay title on public space with people and information

    Project

    Countering Truth Decay

    “Truth Decay,” the diminishing role of facts in public life, poses a threat to evidence-based policymaking and to American democracy. RAND is studying this phenomenon to learn more about its causes, consequences, and potential solutions.

  • education

    Report

    How Do Education Benefits Support Veterans’ Transitions to Civilian Life?

    Today’s new veterans have access to generous and flexible education benefits through the Post-9/11 GI Bill. But it is difficult to determine the effectiveness of these benefits and who is using them. Additional research could help address these gaps and improve understanding of veterans’ needs.

  • Insulin vial and stethoscope, photo by Samara Heisz/Getty Images

    News Release

    Biosimilar Drugs Could Generate $38.4 Billion in Savings over Five Years

    Biosimilar drugs could drive down prices for expensive medicines used to treat illnesses such as cancer and rheumatoid arthritis, with savings estimated to be $38.4 billion or 5.9% of projected total U.S. spending on biologics from 2021 to 2025.

Subscribe to the weekly podcast.

Latest Multimedia

View All Multimedia

Spotlight at RAND

Research Divisions

RAND research is conducted by three divisions that address social and economic policy issues, four federally funded research and development centers (FFRDCs), and by RAND's wholly owned subsidiaries, RAND Europe and RAND Australia.